The University of New Mexico Comprehensive Cancer Center will soon be examining the potential for using cutting-edge radioisotope technology called 177 Lu-PSMA-617 to treat advanced prostate cancer.
The UNM Cancer Center will be one of a few sites in the country participating in a clinical trial to expand the application of theranostic treatment to patients with prostate cancer. This type of treatment is currently used at the cancer center for neuroendocrine tumors.
Theranostics, derived from the words therapy and diagnostic, uses a two-part molecule. One part binds to certain receptors on cancer cells, while the other part is a radioactive ion.
The treatment is a two-part process that first injects the molecule attached to a gallium-68 radioactive isotope that can be imaged to illuminate the cancer cells, which makes them easier to see under Positron Emission Tomography, or PET scans.
But the molecule also marks those cells for the second part of the treatment, a series of injections of the molecule attached to a lutetium-177 radioactive ion that will bind to the cancer cells and destroy them.
The theranostic treatment allows oncologists to target specific cancer cells with less collateral damage to healthy tissues nearby and allows physicians to treat what they see.
Depending on the clinical trial’s outcome, the treatment has the potential of giving men with metastatic prostate cancer more choices. Participants in the clinical trial will have the opportunity of getting this clinical trial treatment on top of the prostate cancer treatment that they would normally get.
Neda Hashemi, MD, leader of the Comprehensive Cancer Center’s Genitourinary Clinical Working Group, explains that the standard treatment for men who have been diagnosed with metastatic prostate cancer starts with hormonal therapy or hormonal therapy plus chemotherapy. This clinical trial, she says, compares the outcomes for men who receive the standard treatments with the outcomes for those who receive one of the standard treatments plus the theranostic treatment.
“The good thing about the clinical trial is [that] all patients are receiving standard of care,” she says.
Patients who undergo the theranostic treatment will receive six treatments with the lutetium-177 to kill the cancer.
The trial will focus on patients who have just recently been diagnosed with metastatic prostate cancer and who haven’t received any other treatments for the disease, she says. The study will include cancer centers from across the world. Roughly 1,100 men will participate.
“The other good thing about the [clinical] trial is that it allows crossover,” Hashemi said. She explains that participants whose cancer is not responding to the treatment they are receiving can elect to try the other treatment. Not every clinical trial allows participants to cross over.
The clinical trial will require a team effort across the UNM Comprehensive Cancer Center.
“It’s very multi-disciplinary,” Hashemi says. “[We] really need a big team working closely together. I could not bring this clinical trial to UNM without the help of our UNM Department of Radiology Nuclear Medicine team and our Radiology team. Everybody worked so hard to open the trial at UNM Cancer Center.” (MSM/Newswise)
